Latest Accurexa Inc. (ACXA) Headlines "New To The

New Post Public Reply Private Reply Replies (0) Message Board

Mar 20, 2015 at 8:22 AM

Latest Accurexa Inc. (ACXA) Headlines

"New To The Street" to Air First of a 6 Part Series Featuring Accurexa, Inc. (ACXA) Marketwired - Wed Mar 18, 9:49AM CDT

"New To The Street" just completed a full 11 minute in-depth interview with George Yu, President and CEO of Accurexa Inc. (OTCQB: ACXA) and its BranchPoint Device. (full story)

FDA Approves Accurexa's Small Business Qualification
ACCESSWIRE - Mon Mar 16, 7:03AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / March 16, 2015 / Accurexa Inc. (the "Company"

(OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that the U.S. FDA (Food and Drug Administration) informed the Company that it qualifies under MDUFA (Medical Device User Fee Amendment) as a Small Business for a reduced or waived fee for medical device submissions made during fiscal year 2015. The Company's Small Business status expires at the close of business September 30, 2015. (full story)

Accurexa's Licensed Patent Application Enters National Phase
ACCESSWIRE - Mon Mar 09, 7:01AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / March 9, 2015 / Accurexa Inc. (the "Company"

(OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that the U.S. Patent Application No. PCT/US2013/052301, Microinjection Catheter; UC Case No. SF2012-063, which the Company exclusively licensed from the University of California, San Francisco (UCSF), has entered national phase applications in the US, European Union, Japan, Canada and China. (full story)

Accurexa's BranchPoint Device Delivering Dopaminergic Stem Cells Published in Molecular Therapy
ACCESSWIRE - Thu Feb 12, 7:00AM CST
SAN FRANCISCO, CA / ACCESSWIRE / February 12, 2015 / Accurexa Inc. (the "Company"

(OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that its BranchPoint device was published in a scientific publication in Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy. Accurexa's BranchPoint device successfully demonstrated the feasibility of delivering human embryonic stem cell-derived dopaminergic neurons in a large animal study. BranchPoint's intracerebral cell transplantation deployed cells to multiple target locations at variable radial distances and depths along the initial brain penetration tract with real-time interventional magnetic resonance image (iMRI) guidance, which can be critical in the treatment of Parkinson's Disease. (full story)

Accurexa Initiates Development of Chemotherapy Product for Brain Cancer
ACCESSWIRE - Wed Feb 04, 7:31AM CST
SAN FRANCISCO,CA / ACCESSWIRE / February 4, 2015 / Accurexa Inc. (the "Company"

(OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that it initiated the development of ACX-31 for the treatment of glioblastoma multiforme, a malignant primary brain tumor. ACX-31 is a chemotherapy product that delivers temozolomide directly to the tumor site with the Company's BranchPoint device. Temozolomide is a generic, approved chemotherapy drug that is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. The Company's BrainPoint device has been developed for the delivery of therapeutics directly into specific regions of the brain and is expected to obtain FDA regulatory approval through a 510(k) submission process. (full story)

Arrowhead Business and Investment Decisions Initiates Coverage on Accurexa Inc.
ACCESSWIRE - Thu Jan 22, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / January 22, 2015 / Arrowhead Business and Investment Decisions, LLC ("Arrowhead"

initiated coverage and published a Due Diligence and Valuation Report on Accurexa Inc. ("Accurexa" or the "Company"

(OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, on December 23, 2014. (full story)

Accurexa Announces Appointment of Daniel A. Lim MD, PhD to its Scientific Advisory Board
ACCESSWIRE - Tue Jan 13, 7:00AM CST
SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2015 / Accurexa Inc. (the "Company"

(OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today the appointment of Daniel A. Lim MD, PhD to its newly formed Scientific Advisory Board. The Scientific Advisory Board will work closely with the Company's management in the development of novel neurological therapies based on the Company's proprietary BranchPoint technology delivering therapeutics directly into specific regions of the brain. (full story)

Accurexa to Present at 2014 Stem Cell Meeting on the Mesa
ACCESSWIRE - Mon Sep 29, 7:00AM CDT
San Francisco, California / ACCESSWIRE / September 29, 2014 / Accurexa Inc. (the "Company"

(OTCQB: ACXA) announced today that George Yu, the Company's President & CEO, will co-present with Daniel Lim, M.D., Ph.D., Assistant Professor of Neurological Surgery, University of California, San Francisco (UCSF) at the 4th Annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, CA. (full story)

Accurexa Announces Exclusive License Agreement With Uc San Francisco
ACCESSWIRE - Wed Sep 17, 8:16AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / September 17, 2014 / Accurexa Inc. (the "Company"

(OTCQB: ACXA) announced today that it has entered into an exclusive license agreement (the "UCSF License"

with the University of California, San Francisco ("UCSF"

in regards to the exclusive global licensing of a medical stereotactic device (the "UCSF device"

, which the Company believes has the potential to significantly improve the delivery of stem cells into the human brain and enhance the efficacy of a wide range of stem cell therapeutics. Beyond stem cells, the platform technology of the UCSF device can also enable the delivery of cell-based therapeutics, gene therapies, and traditional drugs and drug infusions into the human brain. (full story)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avive Partners with Cambridge Fire for Lifesaving Training

Tapping into the Pulse: Avive & Cambridge Fire in Action No fooling around here—Avive Solutions is linking arms with the Cambridge Fire Department to put the city on a faster track to becoming a lifesaver haven. They're rolling out a free CPR and AED training right in the Smith Campus Center, Harvard Square. It's the kind of thing you love to see—getting the community...

Mutare Sharpens Security for Webex Calls with Precision

Control Dialed In: Tailored Call Screening Kicking things up a notch, Mutare is redefining call security by fine-tuning their Voice Security for Webex Calling. Imagine this—custom rules now let organizations shape a security policy down to the very last detail, ensuring unwanted calls don’t slip through the cracks. Wave goodbye to the broad-strokes approach. Precision...

MSP360 Unveils Free Proxmox Backup: A Game Changer?

Backing Up: New Paths for Proxmox Users Ever get that feeling of uncovering something truly worth its weight in gold? That's what MSP360 just dropped on us, with their new backup solution for Proxmox that won’t cost you a dime upfront. They're calling it the Community Edition, and it’s not only free, but it comes with all the bells and whistles for protecting those...

TWP & Commbi Unveil Exclusive Pony Clog Collaboration

A Fusion of Fashion and Functionality Walk down the streets of New York or hustle your way through an airport without worrying about your footwear weighing you down. That's the promise coming from the fresh alliance between TWP and Commbi with their new Pony Clog Collaboration. A blend of high fashion and everyday utility, these clogs aren't just keeping up with the...

TGI Fridays Unveils New 3 For All Menu Options

Hedging Bets on New Dining Strategies Oh, the restaurant battlefield—where one day you're the toast of the town, and the next, you're hustling to keep those seats filled. TGI Fridays, a name as synonymous with casual eats as long as I’ve been in this game, is rolling the dice with a new offering dubbed '3 For All.' Doesn't sound like your average meal deal either....

Alcott HR's Sales Strategy Gets a Boost with New Hire

Alcott HR Ramps Up Sales Firepower Now here's something fresh from the world of human resources outsourcing—Alcott HR has grabbed a new ace for their sales team. Eldin Radoncic is the name you'll want to remember, folks, because he's diving headfirst into the Director of Sales seat at this IRS Certified and ESAC Accredited player based out in good old Farmingdale, New...

Robotics in Cleaning: 2026 Sees Double Adoption Rates

Cleaning Industry Eyes Robotic Solutions Amid Labor Squeeze In a twist that's got industry veterans nodding knowingly, the cleaning industry is tipping towards automation. The recent 2026 Building Service Contractor Market Study reveals a massive leap: 32% of building service contractors (BSCs) plan to embrace robotic floor equipment in the coming year. That's a...

Paula's Choice Elevates Skincare Game with New Campaign

Strategy Meets Skincare: Paula's Choice in the Spotlight Catch this: Paula's Choice just dropped a moisturizer, but it ain't just lotion. No, the Pro-Collagen Peptide Plumping Intensive Moisturizer is here with a punch. And they've got Hannah Waddingham, of 'Ted Lasso' fame, fronting a campaign that screams confidence. Now, that's a way to announce your move at the...

Inovonics Duress Card Enhances Safety for K-12 and Beyond

A New Dawn for Safety in Schools and More It's about time we talk about something more substantial than just beefing up security cameras or tightening door locks. Real-world problems require nimble solutions, and that's where Status Solutions steps in with the Inovonics Duress Card. It's not just another gadget; it's a lightweight, wrist-mounted lifeline designed to say,...

NOAA Taps ICEYE US for Game-Changing SAR Satellite Data

The Strategic Move to SAR Data Imagine this: You’re in the thick of a hurricane, where visibility goes out the window, and traditional satellite data chokes under the crushing weight of clouds and nightfall. That's the precise chaos ICEYE US is cutting through with its Synthetic Aperture Radar (SAR) technology. The latest scuttlebutt is that NOAA's getting cozy with...